Anebulo Pharmaceuticals, Inc. (ANEB) Intrinsic Value

DCF-based fair value calculation with Bear, Base, and Bull scenarios

Popular:

Anebulo Pharmaceuticals, Inc. (ANEB)

View Full Profile →

Intrinsic Value

DCF Not Suitable for ANEB

Market cap ($0.04B) below $1B threshold — DCF not reliable for small-cap/micro-cap stocks.

Alternative Approach:

Use relative valuation (P/E, P/S) vs. peer group.

Frequently Asked Questions

Is ANEB stock undervalued or overvalued?

Insufficient data to compute DCF valuation for ANEB. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.

What is ANEB's intrinsic value?

Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.

How is ANEB's fair value calculated?

Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For ANEB, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.